Zosano Pharma Corporation ZSANQ OTC

Zosano Pharma Corporation (ZSANQ) generated $-27.59M in operating cash flow for fiscal year 2021. After capital expenditures of $5.42M, free cash flow was $-33.01M.

Free cash flow margin was -4205.5% of revenue. Cash conversion ratio was 0.92x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (0/100, Fail) — limited free cash flow weakens the competitive position
• INCOME (10/100) — Cash conversion ratio was 0.92x suggests some earnings are non-cash items

Overall SharesGrow Score: 25/100 with 1/7 criteria passed.